Related Experiment Video
Updated: Nov 26, 2025

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells
Published on: November 18, 2022
Cognitive function improvement with astaxanthin and tocotrienol intake: a randomized, double-blind,
Takahiro Sekikawa1, Yuki Kizawa1, Yanmei Li2
1BGG Japan Co., Ltd., 8F Ginza Kobikicho Building, 8-18-1 Ginza, Chuo-ku, Tokyo 104-0061, Japan.
Abstract:
We examined the effects of the mixed ingestion of astaxanthin derived from Haematococcus pluvialis and tocotrienols on the cognitive function of healthy Japanese adults who feel a memory decline. Forty-four subjects were randomly but equally assigned to the astaxanthin-tocotrienols or placebo group. An astaxanthin-tocotrienols or placebo capsule was taken once daily before or after breakfast for a 12-week intervention period. The primary outcome was composite memory from the Cognitrax cognitive test, and the secondary outcomes were other cognitive functions and subjective symptoms for memory. Each group included 18 subjects in the efficacy analysis (astaxanthin-tocotrienols group, 55.4 ± 7.9 years; placebo group, 54.6 ± 6.9 years). The astaxanthin-tocotrienols group showed a significant improvement in composite memory and verbal memory in Cognitrax at Δ12 weeks compared with the placebo group. Additionally, the astaxanthin-tocotrienols group showed a significant improvement in the subjective symptom of "During the last week, have you had trouble remembering people's names or the names of things?" compared with the placebo group after 12 weeks. No adverse events were observed in this study. The results demonstrated that taking an astaxanthin-tocotrienols combination improves the composite memory and verbal memory of Japanese adults who feel a memory decline (UMIN 000031758).
More Related Videos
03:26Author Spotlight: Improving Anesthesia Protocols for Enhanced Mouse Acupuncture Research
Published on: December 8, 2023
08:53Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
Published on: June 6, 2025
Related Concept Videos
Atherosclerosis III: Management
Bioavailability Study Design: Healthy Subjects Versus Patients
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Bioavailability Study Design: Single Versus Multiple Dose Studies
Alzheimer's Disease: Treatment
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes: